CAR-T细胞治疗难治性风湿免疫病的系统综述
该系统综述纳入12项研究共44例严重难治性风湿病患者,评估CAR-T治疗的疗效与安全性。所有研究均观察到临床应答(个体应答率92%-100%),完全应答在2-16周内出现,无药物缓解持续6-46个月,自身抗体下降80%-99%。安全性方面细胞因子释放综合征(CRS)仅限于1-2级,免疫效应细胞相关神经毒性发生率25%且以1级为主。
要点
- CAR-T在难治性风湿病中实现100%研究水平应答,完全应答2-16周出现。
- 无药物缓解持续6-46个月,自身抗体下降80%-99%。
- CRS仅1-2级,无≥3级事件,神经毒性25%且以1级为主。
核心结论
- CAR-T细胞治疗在难治性风湿免疫病中显示显著疗效,通过全面B细胞清除实现持续缓解。
- 安全性优于肿瘤领域应用,CRS限于1-2级,无≥3级事件,神经毒性罕见且以1级为主。
研究设计与样本
- 遵循PRISMA指南的系统综述(PROSPERO: CRD42025641602),检索5个数据库至2025年2月。
- 纳入12项原始研究,共44例严重难治性风湿病患者,涵盖6种风湿病。
- 采用Joanna Briggs Institute工具和非随机干预研究偏倚风险工具独立评估。
主要发现
- 患者既往广泛暴露(中位5种治疗),包括传统和生物制剂。
- CD19靶向构建体占83%研究,双靶向方法占17%。
- 所有研究均观察到临床应答(个体应答率92%-100%),完全应答在2-16周内出现。
- 无药物缓解持续6-46个月,疾病特异性自身抗体下降80%-99%。
- CRS仅限于1-2级,免疫效应细胞相关神经毒性发生于25%研究,以1级为主。
关键数值与推荐
- 个体应答率92%-100%,完全应答时间2-16周,无药物缓解持续6-46个月。
- 自身抗体下降80%-99%,CRS仅1-2级,无≥3级事件,神经毒性25%研究以1级为主。
临床怎么用
- 对于既往多线治疗失败的严重难治性风湿病患者,CAR-T可考虑作为诱导持续无药物缓解的选择。
- 治疗中需监测CRS和神经毒性,但预期严重不良事件风险较低。
局限性
- 纳入研究样本量小(共44例),证据等级受非随机设计限制。
- 随访时间有限,长期安全性及复发风险未充分评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Current therapeutic paradigms for treatment-refractory rheumatic diseases rely on chronic immunosuppression with variable efficacy and potential for cumulative toxicity. We systematically synthesised evidence on the clinical efficacy, safety and durability of chimeric antigen receptor T-cell (CAR-T) therapy in autoimmune rheumatic diseases. METHODS: We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO: CRD42025641602). Five databases were searched from inception to February 2025 for primary studies investigating CAR-T therapy in autoimmune rheumatic diseases. Two reviewers independently assessed studies using the Joanna Briggs Institute tools and the Risk of Bias in Non-Randomised Studies of Interventions tool. RESULTS: 12 studies encompassed 44 patients with severe treatment-refractory disease across six rheumatic conditions. Patients had extensive prior exposure (median 5 therapies), including conventional and biological agents. Cluster of Differentiation antigen 19 (CD19)-targeted constructs predominated (83% of studies), with emerging dual-target approaches (17%). Universal clinical responses were achieved (100% of studies; individual response rates 92%-100%), with complete responses occurring within 2-16 weeks. Sustained drug-free remissions extended 6-46 months, accompanied by profound autoantibody reductions (80%-99% across disease-specific markers). Safety profiles diverged markedly from oncological experience: cytokine release syndrome (CRS) remained exclusively confined to grades 1-2, while immune effector cell-associated neurotoxicity occurred in 25% of studies, with predominantly grade 1 severity. CONCLUSIONS: CAR-T therapy demonstrates substantial efficacy in treatment-refractory rheumatic diseases, achieving sustained remissions through comprehensive B-cell elimination. Importantly, safety profiles were favourable, with CRS limited to grades 1-2 severity, no grade ≥3 events and rare immune effector cell-associated neurotoxicity, representing markedly superior tolerability compared with oncological applications. PROSPERO REGISTRATION NUMBER: CRD42025641602.
引用
- Santosa A, Tan TC. CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles. RMD Open. 2026. PMID: 41781158. doi:10.1136/rmdopen-2025-006417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。